Post Profile

UK plans 'fast track' for most cost-effective new medicines

LONDON (Reuters) - Britain's healthcare cost agency NICE, which determines if medicines should be used in the state health system, plans to fast-track its recommendations for the most cost-effective new drugs.
read more


Related Posts

NICE backs cut-price Novartis leukaemia drug | Reuters

Medical / Pharmaceutical : PharmaGossip

NICE backs cut-price Novartis leukaemia drug | Reuters (Reuters) - Leukaemia drug Tasigna has been backed by Britain's healthcare cost watchdog after its maker Novartis agreed to discount the treatment's cost of more than 30,000 pou...

NICE rejects pricey leukaemia drugs | Reuters

Medical / Pharmaceutical : PharmaGossip

(Reuters) - Bristol-Myers Squibb's leukaemia drug Sprycel and rival Novartis product Tasigna are not worth using on the state health service, the country's healthcare cost watchdog said. The National Institute for Health and Clinica...

NICE seen at heart of new UK drug pricing system | Reuters

Medical / Pharmaceutical : PharmaGossip

(Reuters) - Britain's cost-effectiveness health watchdog NICE expects to play a central role in a value-based pricing system for new medicines due to take effect from 2014, according to its chief executive. After a government rethin...

UK cost agency wants more data on Bayer's anti-clot drug | Reuters

Medical / Pharmaceutical : PharmaGossip

Jan 9 (Reuters) - Britain's health costs watchdog is asking Bayer for more information on its anti-clotting drug Xarelto before deciding whether to recommend it for use on the state health service. The National Institute for Health ...

Pfizer loses appeal in UK patent case over use of Lyrica drug for pain

Health : Reuters: Health

LONDON (Reuters) - Pfizer suffered a setback in Britain on Thursday when the Court of Appeal in London ruled against it in a patent case over the use of its $5 billion-a-year drug Lyrica for pain relief.


Copyright © 2016 Regator, LLC